Sansure Biotech Management
Management criteria checks 4/4
Sansure Biotech's CEO is Lizhong Dai, appointed in Jul 2019, has a tenure of 5.58 years. directly owns 33.21% of the company’s shares, worth CN¥4.35B. The average tenure of the management team and the board of directors is 5.6 years and 5.6 years respectively.
Key information
Lizhong Dai
Chief executive officer
CN¥700.6k
Total compensation
| CEO salary percentage | n/a |
| CEO tenure | 5.6yrs |
| CEO ownership | 33.2% |
| Management average tenure | 5.6yrs |
| Board average tenure | 5.6yrs |
Recent management updates
Recent updates
Investors Could Be Concerned With Sansure Biotech's (SHSE:688289) Returns On Capital
Feb 08
Some Confidence Is Lacking In Sansure Biotech Inc.'s (SHSE:688289) P/E
Jan 08Sansure Biotech's (SHSE:688289) Problems Go Beyond Weak Profit
Nov 03Sansure Biotech Inc.'s (SHSE:688289) 39% Price Boost Is Out Of Tune With Earnings
Oct 09Sansure Biotech (SHSE:688289) Could Be Struggling To Allocate Capital
Oct 03Is Sansure Biotech (SHSE:688289) A Risky Investment?
Sep 12Sansure Biotech Inc. (SHSE:688289) Investors Are Less Pessimistic Than Expected
Aug 21Sansure Biotech (SHSE:688289) May Have Issues Allocating Its Capital
Jun 03Why Sansure Biotech's (SHSE:688289) Soft Earnings Are Just The Beginning Of Its Problems
May 03Sansure Biotech Inc.'s (SHSE:688289) Business Is Trailing The Industry But Its Shares Aren't
Apr 26Sansure Biotech's (SHSE:688289) Returns On Capital Are Heading Higher
Feb 28CEO
Lizhong Dai (56 yo)
5.6yrs
Tenure
CN¥700,600
Compensation
Mr. Lizhong Dai is Chairman of the Board and General Manager of Sansure Biotech Inc. from July 2019.
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Chairman of the Board & GM | 5.6yrs | CN¥700.60k | 33.21% CN¥ 4.3b | |
| CFO, Deputy GM & Director | 5.6yrs | CN¥1.68m | 0.067% CN¥ 8.8m | |
| Deputy GM | 2yrs | CN¥2.28m | no data | |
| Deputy GM & Director | 5.6yrs | CN¥439.70k | 0.026% CN¥ 3.5m | |
| Deputy GM & Director | 5.6yrs | CN¥666.90k | 0.054% CN¥ 7.1m | |
| Deputy GM & Director | no data | CN¥557.80k | 0.035% CN¥ 4.6m | |
| Deputy General Manager | 5.6yrs | CN¥970.40k | 0.016% CN¥ 2.0m | |
| Deputy General Manager | 3.5yrs | CN¥1.55m | 0.026% CN¥ 3.4m | |
| Deputy General Manager | 3.5yrs | CN¥2.34m | 0.025% CN¥ 3.2m | |
| Deputy General Manager | 5.6yrs | CN¥522.60k | 0.019% CN¥ 2.4m | |
| Deputy General Manager | 2.6yrs | CN¥1.43m | 0.041% CN¥ 5.3m | |
| Deputy General Manager | 2.3yrs | CN¥621.60k | 0.022% CN¥ 2.9m |
5.6yrs
Average Tenure
47yo
Average Age
Experienced Management: 688289's management team is seasoned and experienced (5.6 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Chairman of the Board & GM | 5.6yrs | CN¥700.60k | 33.21% CN¥ 4.3b | |
| CFO, Deputy GM & Director | 5yrs | CN¥1.68m | 0.067% CN¥ 8.8m | |
| Deputy GM & Director | 5.6yrs | CN¥439.70k | 0.026% CN¥ 3.5m | |
| Deputy GM & Director | 4.3yrs | CN¥666.90k | 0.054% CN¥ 7.1m | |
| Deputy GM & Director | 2.6yrs | CN¥557.80k | 0.035% CN¥ 4.6m | |
| Chairman of Supervisory Board | 5.6yrs | no data | 0.035% CN¥ 4.6m | |
| Independent Director | 5.6yrs | CN¥80.00k | no data | |
| Director | 5.6yrs | no data | no data | |
| Supervisor | 2.6yrs | no data | 0.00040% CN¥ 52.4k |
5.6yrs
Average Tenure
45yo
Average Age
Experienced Board: 688289's board of directors are considered experienced (5.6 years average tenure).
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/02/16 23:55 |
| End of Day Share Price | 2025/02/14 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Sansure Biotech Inc. is covered by 5 analysts. 3 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Shiyu Chen | China International Capital Corporation Limited |
| Zhu Chen | Citic Securities Co., Ltd. |
| Shuo Song | Citic Securities Co., Ltd. |